Related Experiment Video

Updated: Jun 15, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth

Shicheng Liu1, Yiming Yuan, Yutaka Okumura

  • 1Research and Development Department, Nipro Patch Co., Ltd., 8-1, Minamisakae-cho, Kasukabe, Saitama 344-0057, Japan. liusc59@yahoo.co.jp

Biochemical and Biophysical Research Communications
|March 9, 2010
PubMed

Insights

Camptothecin, a topoisomerase I inhibitor, effectively targets the androgen receptor (AR) in prostate cancer cells. This novel mechanism inhibits cancer growth by disrupting AR function and lowering prostate-specific antigen (PSA) levels.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The androgen receptor (AR) is a key therapeutic target in metastatic prostate cancer.
  • Targeting AR signaling is crucial for effective prostate cancer treatment.

Purpose of the Study:

  • To investigate the effect of camptothecin on androgen-responsive prostate cancer cell growth.
  • To elucidate the molecular mechanisms by which camptothecin affects AR signaling.

Main Methods:

  • Treatment of LNCaP and PC-3/AR cells with camptothecin.
  • Assessment of AR protein expression, phosphorylation, and transcriptional activity.
  • Analysis of AR-HSP90 interaction, androgen binding, and nuclear translocation.
  • Measurement of prostate-specific antigen (PSA) levels and promoter activity.

Main Results:

  • Camptothecin inhibited both wild-type and mutated AR protein expression.
  • It reduced androgen-mediated AR phosphorylation and transcriptional activity.
  • Camptothecin disrupted AR association with HSP90, impeded androgen binding, and blocked nuclear translocation.
  • Downregulation of AR target gene PSA and inhibition of PSA promoter activity were observed.

Conclusions:

  • Camptothecin selectively inhibits androgen-responsive prostate cancer cell growth.
  • It acts as a novel AR-disrupting agent, in addition to its genotoxic effects.
  • Camptothecin shows potential as a novel therapeutic candidate for prostate cancer treatment.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...